Cargando…
Clinical trials of new drugs for Alzheimer disease
Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of the disease and continual increase in patient numbers, developing effective therapies to treat AD has become urgent. Presently, the drugs available for AD treatment, including cholinesterase inhibitors and an anta...
Autores principales: | Huang, Li-Kai, Chao, Shu-Ping, Hu, Chaur-Jong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943903/ https://www.ncbi.nlm.nih.gov/pubmed/31906949 http://dx.doi.org/10.1186/s12929-019-0609-7 |
Ejemplares similares
-
Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
por: Huang, Li-Kai, et al.
Publicado: (2023) -
Clinical Trials of New Drugs for Vascular Cognitive Impairment and Vascular Dementia
por: Linh, Tran Thanh Duy, et al.
Publicado: (2022) -
Drug candidates in clinical trials for Alzheimer’s disease
por: Hung, Shih-Ya, et al.
Publicado: (2017) -
Current and Future Trends in Biomarkers for the Early Detection of Alzheimer’s Disease in Asia: Expert Opinion
por: Kandiah, Nagaendran, et al.
Publicado: (2022) -
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
por: Vassar, Robert
Publicado: (2014)